Myriad Genetics (MYGN)
NASDAQ:MYGN
Want to see MYGN full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.04Last Year’s EPS
0.05Same Quarter Last Year
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized meaningful progress in core growth engines (double-digit hereditary cancer growth, robust GeneSight performance, solid gross margins and a deep product pipeline) and management reaffirmed full-year guidance and positive adjusted EBITDA expectations. Near-term pressures include a Q1 adjusted EBITDA loss, higher operating expense due to accelerated commercial hiring, and a notable prenatal revenue decline. Management is investing to drive back-half acceleration but execution (sales ramp, MRD adoption, payer reimbursement) will determine pace of recovery. On balance, the positives around market share gains, product launches and revenue guidance outweigh the short-term profitability and prenatal headwinds.Company Guidance
Revenue within Guidance
Q1 revenue of $200.4 million, up ~2% year-over-year and within the company's Q1 guidance range; management reaffirmed full-year revenue guidance of $860M–$880M.
Strong Hereditary Cancer Testing Growth
Hereditary cancer testing volume grew 14% year-over-year (accelerating from 11% in Q4). Affected population volume grew ~10% YoY and unaffected population volume grew ~16% YoY, delivering market share gains.
GeneSight (Mental Health) Momentum
GeneSight revenue of $38.3 million, up 24% year-over-year, with test volume up 7% YoY; ordering base reached a record >39,000 clinicians and reimbursement improvements (biomarker legislation) lifted ASPs and revenue.
Healthy Gross Margin Profile
Reported adjusted gross margin of ~68.7%–69% in Q1 (roughly +20 basis points YoY), in line with full-year guidance and supporting ongoing strategic investments.
Pipeline and New Product Progress
Multiple launches on track: Precise MRD (alpha launch for breast in March) showing promising early adoption and assay performance; Prolaris+AI on track to launch in June; FirstGene in early access with strong CONNECTOR enrollment and a planned full commercial launch in H2 2026. Precise MRD sensitivity reported to detect down to 1 part per million.
Commercial Expansion and Investments
Expanded commercial team by over 100 account executives year-over-year and committed ~$35 million of investment over the next several years to strengthen commercial capabilities, demand generation and launch execution to support back-half acceleration.
Operational and Balance Sheet Strength
MRD assay yields and turnaround times tracking to internal targets; company reports access to $199 million in capital and reaffirmed adjusted EBITDA target range of $37M–$49M for 2026.
Average Revenue Per Test Improvement
Average revenue per test improved ~2% year-over-year in Q1, driven by product mix (hereditary cancer growth) and improved reimbursement in GeneSight.
MYGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MYGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $5.03 | $4.11 | -18.29% |
Feb 23, 2026 | $4.38 | $4.43 | +1.14% |
Nov 03, 2025 | $8.18 | $6.46 | -21.03% |
Aug 05, 2025 | $3.87 | $5.67 | +46.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Myriad Genetics (MYGN) report earnings?
Myriad Genetics (MYGN) is schdueled to report earning on Jul 30, 2026, TBA (Confirmed).
What is Myriad Genetics (MYGN) earnings time?
Myriad Genetics (MYGN) earnings time is at Jul 30, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MYGN EPS forecast?
MYGN EPS forecast for the fiscal quarter 2026 (Q2) is -0.04.